Alpha lipoic acid (ALA) is an antioxidant compound that has been investigated for its potential role in supporting or treating Multiple Sclerosis (MS), a chronic autoimmune disorder affecting the central nervous system. The rationale for its use is primarily scientific, based on ALA’s ability to reduce oxidative stress and inflammation, both of which are involved in the pathogenesis of MS. Several preclinical studies have demonstrated that ALA can reduce immune cell infiltration and demyelination in animal models of MS, such as experimental autoimmune encephalomyelitis (EAE).

Small-scale human studies provide preliminary evidence for benefit. For example, a randomized controlled pilot study published in Multiple Sclerosis (2005) showed that oral ALA supplementation reduced serum markers of inflammation in people with MS. Another phase II trial (Neuroimmunomodulation, 2017) found that 1200 mg daily of ALA over two years slowed brain atrophy in secondary progressive MS compared to placebo. However, these studies are limited by small sample sizes and short durations, and meta-analyses have concluded that the quality of evidence is low to moderate, with a need for larger, well-controlled trials to confirm efficacy and safety.

In summary, while there is scientific rationale and some early clinical evidence supporting the use of ALA in MS, the evidence is preliminary. ALA is not considered a standard therapy for MS, and its use should be considered experimental.